Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease

J Alzheimers Dis. 2010;22(2):569-79. doi: 10.3233/JAD-2010-100768.

Abstract

Impaired glucose regulation is a defining characteristic of type 2 diabetes mellitus (T2DM) pathology and has been linked to increased risk of cognitive impairment and dementia. Although the benefits of aerobic exercise for physical health are well-documented, exercise effects on cognition have not been examined for older adults with poor glucose regulation associated with prediabetes and early T2DM. Using a randomized controlled design, twenty-eight adults (57-83 y old) meeting 2-h tolerance test criteria for glucose intolerance completed 6 months of aerobic exercise or stretching, which served as the control. The primary cognitive outcomes included measures of executive function (Trails B, Task Switching, Stroop, Self-ordered Pointing Test, and Verbal Fluency). Other outcomes included memory performance (Story Recall, List Learning), measures of cardiorespiratory fitness obtained via maximal-graded exercise treadmill test, glucose disposal during hyperinsulinemic-euglycemic clamp, body fat, and fasting plasma levels of insulin, cortisol, brain-derived neurotrophic factor, insulin-like growth factor-1, amyloid-β (Aβ40 and Aβ42). Six months of aerobic exercise improved executive function (MANCOVA, p=0.04), cardiorespiratory fitness (MANOVA, p=0.03), and insulin sensitivity (p=0.05). Across all subjects, 6-month changes in cardiorespiratory fitness and insulin sensitivity were positively correlated (p=0.01). For Aβ42, plasma levels tended to decrease for the aerobic group relative to controls (p=0.07). The results of our study using rigorous controlled methodology suggest a cognition-enhancing effect of aerobic exercise for older glucose intolerant adults. Although replication in a larger sample is needed, our findings potentially have important therapeutic implications for a growing number of adults at increased risk of cognitive decline.

Trial registration: ClinicalTrials.gov NCT00220441.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Alzheimer Disease / etiology*
  • Amyloid beta-Peptides / blood
  • Brain-Derived Neurotrophic Factor / blood
  • Cognition Disorders / etiology*
  • Cognition Disorders / rehabilitation*
  • Executive Function / physiology
  • Exercise Therapy / methods*
  • Exercise*
  • Female
  • Follow-Up Studies
  • Glucose Clamp Technique / methods
  • Glucose Intolerance / complications*
  • Glucose Intolerance / rehabilitation
  • Heart Rate / physiology
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Male
  • Memory / physiology
  • Middle Aged
  • Neuropsychological Tests
  • Oxygen Consumption / physiology
  • Risk Factors

Substances

  • Amyloid beta-Peptides
  • Brain-Derived Neurotrophic Factor
  • Insulin-Like Growth Factor I

Associated data

  • ClinicalTrials.gov/NCT00220441